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Recent studies have shown that tumor immune evasion
mechanisms significantly contribute to immunotherapy
failure. Emerging data is indicating that tumor-associated
dendritic cells (DCs) undergo phenotypic tolerization and
promote the differentiation and activation of regulatory
T cell (Treg) populations to generate local immune
subversion. The critical role of DCs in orchestrating anti-
tumor immunity suggests that the signaling pathways that
regulate DC tolerogenesis may be promising targets for
pharmacologically augmenting immunotherapy efficacy.
Previous work has shown that the b-catenin signaling
pathway plays a potential role in the DC tolerization
process. Others have demonstrated that the DC-expressed
enzyme, indoleamine 2,3-dioxygenase (IDO), promotes
tumor-induced immune tolerance by catalyzing the
conversion of the amino acid tryptophan into kynurenine.
Other investigators have demonstrated melanomas to
upregulate the expression of several Wnt ligands during
their malignant transformation. Using a transgenic murine
model of melanoma, we have determined that melanoma-
associated DCs exhibit elevated levels of expression of
IDO and other b-catenin target genes and demonstrate
diminished T cell stimulatory capacity in vitro. Further
studies have shown that Wnt3a and Wnt5a induce the
expression and enzymatic activity of IDO in myeloid DCs
(mDCs) in a b-catenin-dependent fashion while IDO
reporter assays suggest this process to be mediated
by direct promoter activation. This data suggest the Wnt-
b-catenin signaling pathway to be a potential target for
suppressing melanoma-induced DC tolerization and
enhancing anti-tumor immunity. Indeed, both small
molecule inhibition and genetic silencing of the PORCN
acyl transferase enzyme which is necessary for Wnt
secretion, abrogated B16 melanoma paracrine induction of
b-catenin signaling and IDO expression by local mDCs.
Further studies have shown PORCN-silenced B16 melano-
mas to exhibit reduced tumorigenecity in vivo and that
this effect correlated with decreased mDC IDO expression
and reduced levels of local Tregs. We therefore hypothe-
size that melanoma-expressed Wnt ligands induce DC
tolerogenesis and stimulate b-catenin-dependent IDO
expression and subsequent Treg generation in the tumor
microenvironment, resulting in the development of an
immunotolerant state and ultimately allowing for disease
progression. Further, we propose that the pharmacological
inhibition of this pathway can reverse this mechanism of
immune evasion and enhance other immunotherapeutic
approaches. Future work will include testing the ability
of the small molecule PORCN inhibitor to stimulate the
generation of tumor antigen-specific T cell responses in
an autochthonous transgenic melanoma model.
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